In Vitro Activity of CEM-102 (fusidic Acid) Against Prevalent Clones and Resistant Phenotypes of Staphylococcus Aureus

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2013 Jun 19

PMID 23774441

Citations 5

Authors

D F Sahm

J Deane

C M Pillar

P Fernandes

Affiliations

Soon will be listed here.

Abstract

Clinical development of CEM-102 (fusidic acid) has recently begun in the United States for chronic oral treatment of prosthetic joint infections. To support this development, the in vitro activity of fusidic acid against important Staphylococcus aureus clones and resistance phenotypes was determined. Against 51 such isolates, the modal fusidic acid MIC was 0.12 μg/ml (range, 0.06 to 0.25 μg/ml for 49 isolates). This level of in vitro fusidic acid activity underscores the potential clinical utility of this compound in the United States.

Citing Articles

The implication of Mycobacterium tuberculosis-mediated metabolism of targeted xenobiotics.

Singh V, Dziwornu G, Chibale K Nat Rev Chem. 2023; 7(5):340-354.

PMID: 37117810 PMC: 10026799. DOI: 10.1038/s41570-023-00472-3.

Crystal Structure of Elongation Factor G1.

Gao X, Yu X, Zhu K, Qin B, Wang W, Han P Front Mol Biosci. 2021; 8:667638.

PMID: 34540889 PMC: 8446442. DOI: 10.3389/fmolb.2021.667638.

The global prevalence of fusidic acid resistance in clinical isolates of Staphylococcus aureus: a systematic review and meta-analysis.

Hajikhani B, Goudarzi M, Kakavandi S, Amini S, Zamani S, van Belkum A Antimicrob Resist Infect Control. 2021; 10(1):75.

PMID: 33933162 PMC: 8088720. DOI: 10.1186/s13756-021-00943-6.

Activities of Combinations of Antistaphylococcal Antibiotics with Fusidic Acid against Staphylococcal Biofilms in Static and Dynamic Models.

Siala W, Rodriguez-Villalobos H, Fernandes P, Tulkens P, Van Bambeke F Antimicrob Agents Chemother. 2018; 62(7).

PMID: 29712650 PMC: 6021669. DOI: 10.1128/AAC.00598-18.

Fusidic Acid: A Bacterial Elongation Factor Inhibitor for the Oral Treatment of Acute and Chronic Staphylococcal Infections.

Fernandes P Cold Spring Harb Perspect Med. 2016; 6(1):a025437.

PMID: 26729758 PMC: 4691801. DOI: 10.1101/cshperspect.a025437.

References

Hiramatsu K, Hanaki H, Ino T, YABUTA K, Oguri T, Tenover F . Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997; 40(1):135-6. DOI: 10.1093/jac/40.1.135. View

ONeill A, McLaws F, Kahlmeter G, Henriksen A, Chopra I . Genetic basis of resistance to fusidic acid in staphylococci. Antimicrob Agents Chemother. 2007; 51(5):1737-40. PMC: 1855526. DOI: 10.1128/AAC.01542-06. View

Castanheira M, Watters A, Bell J, Turnidge J, Jones R . Fusidic acid resistance rates and prevalence of resistance mechanisms among Staphylococcus spp. isolated in North America and Australia, 2007-2008. Antimicrob Agents Chemother. 2010; 54(9):3614-7. PMC: 2934946. DOI: 10.1128/AAC.01390-09. View

. Staphylococcus aureus resistant to vancomycin--United States, 2002. MMWR Morb Mortal Wkly Rep. 2002; 51(26):565-7. View

Pfaller M, Castanheira M, Sader H, Jones R . Evaluation of the activity of fusidic acid tested against contemporary Gram-positive clinical isolates from the USA and Canada. Int J Antimicrob Agents. 2009; 35(3):282-7. DOI: 10.1016/j.ijantimicag.2009.10.023. View

Brown E, Thomas P . Fusidic acid resistance in Staphylococcus aureus isolates. Lancet. 2002; 359(9308):803. DOI: 10.1016/S0140-6736(02)07869-8. View

Morales G, Picazo J, Baos E, Candel F, Arribi A, Pelaez B . Resistance to linezolid is mediated by the cfr gene in the first report of an outbreak of linezolid-resistant Staphylococcus aureus. Clin Infect Dis. 2010; 50(6):821-5. DOI: 10.1086/650574. View

ONeill A, Larsen A, Skov R, Henriksen A, Chopra I . Characterization of the epidemic European fusidic acid-resistant impetigo clone of Staphylococcus aureus. J Clin Microbiol. 2007; 45(5):1505-10. PMC: 1865894. DOI: 10.1128/JCM.01984-06. View

Tsuji B, Okusanya O, Bulitta J, Forrest A, Bhavnani S, Fernandez P . Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis. 2011; 52 Suppl 7:S513-9. DOI: 10.1093/cid/cir166. View

10.

Jones R, Mendes R, Sader H, Castanheira M . In vitro antimicrobial findings for fusidic acid tested against contemporary (2008-2009) gram-positive organisms collected in the United States. Clin Infect Dis. 2011; 52 Suppl 7:S477-86. DOI: 10.1093/cid/cir163. View

11.

Casey A, Lambert P, Elliott T . Staphylococci. Int J Antimicrob Agents. 2007; 29 Suppl 3:S23-32. DOI: 10.1016/S0924-8579(07)72175-1. View

12.

Craft J, Moriarty S, Clark K, Scott D, Degenhardt T, Still J . A randomized, double-blind phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid for the treatment of acute bacterial skin and skin structure infections. Clin Infect Dis. 2011; 52 Suppl 7:S520-6. DOI: 10.1093/cid/cir167. View

13.

Sakoulas G, Moellering Jr R . Increasing antibiotic resistance among methicillin-resistant Staphylococcus aureus strains. Clin Infect Dis. 2008; 46 Suppl 5:S360-7. DOI: 10.1086/533592. View

14.

Hayden M, Rezai K, Hayes R, Lolans K, Quinn J, Weinstein R . Development of Daptomycin resistance in vivo in methicillin-resistant Staphylococcus aureus. J Clin Microbiol. 2005; 43(10):5285-7. PMC: 1248493. DOI: 10.1128/JCM.43.10.5285-5287.2005. View